NCT04880746
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Efficacy and Safety of Cladribine Combined With BEAC ( Semustine, Etoposide, Cytarabine, Cyclophosphamide) Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Ruijin Hospital·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Peripheral T-cell Lymphoma
- Drug/Device/Intervention
- BEAC
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Ruijin Hospital
- Location
- Shanghai, China
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Oct 17, 2020
- End date
- Oct 17, 2025
- Enrollment
- 266 participants
Primary outcome
Progression free survival
Summary
This multi-center clinical study will evaluate the efficacy and safety of Cladribine Combined
 With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma.
ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT04880746
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT04880746 through Pure Global AI's free database. This Phase 3 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 266 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.